{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-052579","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2024-12-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.295680+00:00","generated_at":"2026-05-28T22:36:47.699460+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Pfizer terminates hemophilia A gene therapy deal with Sangamo; milestone payments lost","bullets":["Pfizer notified Sangamo of termination for convenience effective April 21, 2025; no BLA or MAA to be submitted.","Sangamo forfeits up to $220M in remaining milestones and all future royalties (14-20% of net sales).","Sangamo receives exclusive license back to develop and commercialize SB-525; Pfizer gets low single digit royalties.","Sangamo plans to seek a new partner to advance regulatory filings for giroctocogene fitelparvovec.","Pfizer had paid $125M already ($70M upfront + $55M milestones); remaining program rights revert."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-052579","json":"https://secwatch.observer/filing/0001628280-24-052579.json","markdown":"https://secwatch.observer/filing/0001628280-24-052579.md","text":"https://secwatch.observer/filing/0001628280-24-052579.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000162828024052579/0001628280-24-052579-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000162828024052579/sgmo-20241222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T22:36:47.699460+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}